EGFR and non-small cell lung carcinoma: Therefore, we conducted this study to evaluate the effectiveness and adverse events (AEs) of TKIs as a first-line treatment for advanced NSCLC with EGFR mutations at Nghe An Oncology Hospital, Vietnam.